BIO-TECHNE EV/EBIT TECH

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2011.

Today, Oct 23, 2026: 44.9×
10-year median: 44.6×
Against its 10-year history: 53rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 21.6× to 89.7×
Peer median: 17.8×

BIO-TECHNE's EV/EBIT is 44.9× as of Oct 23, 2026.

That is above its ten-year median of 44.6×, close to the middle of its last ten years.

Over that time it ranged from 21.6× in May 2025 to 89.7× in Jul 2021.

The median for 10 biotech stocks of a similar size is 17.8×.

EV/EBIT over time

median 44.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	44.9×	26.6×	51.5×
2025	31.6×	21.6×	46.7×
2024	44.3×	34.8×	48.4×
2023	41.3×	31.0×	53.7×
2022	44.5×	36.7×	62.9×
2021	78.3×	69.1×	89.7×
2020	70.8×	41.6×	74.4×
2019	56.1×	38.4×	57.6×
2018	37.7×	36.7×	51.4×
2017	39.6×	26.0×	40.7×
2016	27.2×	24.6×	28.3×
2015	23.7×	21.2×	27.0×
2014	22.3×	18.6×	22.3×
2013	21.1×	13.6×	21.1×
2012	14.6×	13.8×	15.8×
2011	14.4×	13.1×	15.6×

Against its peers

Companies in Biotechnology nearest BIO-TECHNE's size, closest first, today.

Company	EV/EBIT
TECHBIO-TECHNE	44.9×
RGENRepligen	160×
KRYSKrystal Biotech	42.4×
HALOHalozyme Therapeutics	17.4×
NBIXNeurocrine Biosciences	18.2×
EXELExelixis	15.4×
INCYIncyte	10.1×
UTHRUnited Therapeutics	16.1×
ALNYAlnylam Pharmaceuticals	27.9×
ONCBeOne Medicines	42.2×
ADMAAdma Biologics	10.9×
Peer median	17.8×

Where BIO-TECHNE ranks

#15of 17Biotech stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on BIO-TECHNE

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.